首页|丙酸倍氯米松鼻喷雾剂联合鼻渊合剂治疗风寒湿型变应性鼻炎的临床研究

丙酸倍氯米松鼻喷雾剂联合鼻渊合剂治疗风寒湿型变应性鼻炎的临床研究

扫码查看
目的 探讨丙酸倍氯米松鼻喷雾剂与鼻渊合剂联合治疗风寒湿型变应性鼻炎的临床效果.方法 选取2021 年6 月至2023 年5月江苏省海安市中医院耳鼻喉科收治的126 例风寒湿型变应性鼻炎患者为研究对象,根据随机数字表法将其分为西药组(丙酸倍氯米松)、中药组(鼻渊合剂)及联合组(丙酸倍氯米松联合鼻渊合剂),各42 例.西药组采取丙酸倍氯米松鼻喷雾剂治疗,中药组采取鼻渊合剂治疗,联合组则采取两药联合治疗.治疗4 周后,比较三组临床疗效及三组治疗前后的鼻黏膜症状[鼻症状视觉模拟评分法(VAS)评分、鼻症状总积分表(TNSS)、鼻伴随症状总分表(TNNSS)]、鼻黏膜炎症标志物[黏蛋白-5AC(MUC5AC)、白细胞介素-6(IL-6)、γ 干扰素(IFN-γ)]、鼻功能[总鼻气道阻力(NAR)、鼻腔最小横断面积(NMCA)和0~5 cm 鼻腔容积(0~5 cmNCV)].结果 联合组疗效优于西药组和中药组(P<0.05).治疗后,三组鼻症状VAS、TNSS、TNNSS 评分均低于治疗前,且联合组低于西药组和中药组(P<0.05).治疗后,三组MUC5AC、IL-6 水平均低于治疗前,IFN-γ 水平高于治疗前,且联合组MUC5AC、IL-6 水平低于西药组和中药组,IFN-γ水平高于西药组和中药组(P<0.05).治疗后,三组NAR 低于治疗前,NMCA、0~5 cmNCV 高于治疗前,且联合组NAR 低于西药组和中药组,NMCA、0~5 cmNCV 高于西药组和中药组(P<0.05).结论 丙酸倍氯米松鼻喷雾剂与鼻渊合剂联合治疗风寒湿型变应性鼻炎显示出良好的效果,可有效减轻鼻黏膜炎症反应,提高患者的生活质量,在临床上具有较大的推广价值.
Clinical study of Beclomethasone Dipropionate Nasal Spray combined with Biyuan Mixture in the treatment of allergic rhinitis with wind-cold-dampness obstruction pattern
Objective lo investigate the clinical effect of Beclomethasone Dipropionate Nasal Spray combined with Biyuan Mixture in the treat-ment of allergic rhinitis with wind-cold-dampness obstruction pattern.Methods A total of 126 allergic rhinitis patients with wind-cold-dampness obstruction pattern admitted to the Department of Otolaryngology,Haian Traditional Chinese Medicine Hospital,Jiangsu Province from June 2021 to May 2023 were selected as the study objects.According to random number table method,they were divided into western medicine group,Chinese medicine group,and combined group,each with 42 cases.The western medicine group was treated with Beclomethasone Dipropionate Nasal Spray,the Chinese medicine group was treated with Biyuan Mixture,and the combined group was treated with two drugs.After four weeks of treatment,the clinical efficacy and the nasal mucosal symptoms(nasal symptoms visual analogue scale[VAS]score,total nasal symptoms score[TNSS],total nasal and non-nasal symptom score[TINNSS]),markers of nasal mucosal inflammation(mucoprotein-5AC[MUC5AC],interleukin-6[IL-6],interfer-on-γ[IFN-γ]),and nasal function(nasal airway resistance[NAR],nasal minimum cross-sectional area[NMCA],and 0-5 cm nasal volume[0-5 cmNCV])of the three groups before and after treatment were compared.Results The curative effect of combined group was better than that of west-ern medicine group and Chinese medicine group(P<0.05).After treatment,the nasal symptoms VAS,TNSS,and TNNSS scores of the three groups were lower than those before treatment,and those of combined group were lower than those of western medicine group and Chinese medicine group(P<0.05).After treatment,the levels of MUC5AC and IL-6 in the three groups were lower than those before treatment,and the levels of IFN-γwere higher than that before treatment,and the levels of MUC5AC and IL-6 in the combined group were lower than those in the western medicine group and the Chinese medicine group,and the level of IFN-γ was higher than those in the western medicine group and the Chinese medicine group(P<0.05).After treatment,NAR in the three groups was lower than that before treatment,NMCA,0-5 cmNCV were higher than those before treatment,and NAR in the combined group was lower than that in western medicine group and Chinese medicine group,and NMCA,0-5 cmNCV were higher than those in the western medicine group and Chinese medicine group(P<0.05).Conclusion The combination of Beclomethasone Dipropionate Nasal Spray and Biyuan Mixture in the treatment of allergic rhinitis with wind-cold-dampness obstruction pattern shows a good effect,can effectively reduce the nasal mucosal inflammation,improve the quality of life of patients,and has a greater value in clinical promotion.

Allergic rhinitisBeclomethasone Dipropionate Nasal SprayBiyuan MixtureCombination treatmentClinical efficacy

姜晖、钟永玲、田艳红

展开 >

江苏省海安市中医院耳鼻喉科,江苏海安 226600

变应性鼻炎 丙酸倍氯米松鼻喷雾剂 鼻渊合剂 联合治疗 疗效

江苏省自然科学基金

BK20180141

2024

中国医药导报
中国医学科学院

中国医药导报

CSTPCD
影响因子:1.759
ISSN:1673-7210
年,卷(期):2024.21(15)